Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case–control study

Joanne Kotsopoulos, Tomasz Huzarski, Jacek Gronwald, Pal Moller, Henry T. Lynch, Susan L. Neuhausen, Leigha Senter, Rochelle Demsky, William D. Foulkes, Charis Eng, Beth Karlan, Nadine Tung, Christian F. Singer, Ping Sun, Jan Lubinski, Steven A. Narod

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Many BRCA1 mutation carriers undergo elective surgical oophorectomy (often before menopause) to manage their elevated risk of developing ovarian cancer. It is important to clarify whether or not the use of hormone replacement therapy (HRT) to mitigate the symptoms associated with surgical or natural menopause is safe in women with an inherited BRCA1 mutation and no personal history of breast or ovarian cancer. We conducted a case–control analysis of 432 matched pairs of women with a BRCA1 mutation. Detailed information on HRT use after menopause (duration, type, age at first/last use, formulation) was obtained from a research questionnaire administered at the time of study enrollment. Conditional logistic regression was used to estimate the odds ratio (OR) and 95 % confidence intervals (CI) associated with HRT use. The mean duration of HRT use after menopause was 4.3 years among the cases and 4.4 years among the controls (P = 0.83). The adjusted OR for breast cancer comparing all women who ever used HRT to those who never used HRT was 0.80 (95 % CI 0.55–1.16; P = 0.24). Findings did not differ by type of menopause (natural vs. surgical), by recency of use, by duration of use, and by formulation type. These findings suggest that a short course of HRT should not be contra-indicated for BRCA1 mutation carriers who have undergone menopause and who have no personal history of cancer.

Original languageEnglish
Pages (from-to)365-373
Number of pages9
JournalBreast Cancer Research and Treatment
Volume155
Issue number2
DOIs
StatePublished - Jan 1 2016

Fingerprint

Hormone Replacement Therapy
Menopause
Breast Neoplasms
Mutation
Ovarian Neoplasms
Odds Ratio
Confidence Intervals
Matched-Pair Analysis
Time and Motion Studies
Ovariectomy
Logistic Models
Research
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers : a case–control study. / Kotsopoulos, Joanne; Huzarski, Tomasz; Gronwald, Jacek; Moller, Pal; Lynch, Henry T.; Neuhausen, Susan L.; Senter, Leigha; Demsky, Rochelle; Foulkes, William D.; Eng, Charis; Karlan, Beth; Tung, Nadine; Singer, Christian F.; Sun, Ping; Lubinski, Jan; Narod, Steven A.

In: Breast Cancer Research and Treatment, Vol. 155, No. 2, 01.01.2016, p. 365-373.

Research output: Contribution to journalArticle

Kotsopoulos, J, Huzarski, T, Gronwald, J, Moller, P, Lynch, HT, Neuhausen, SL, Senter, L, Demsky, R, Foulkes, WD, Eng, C, Karlan, B, Tung, N, Singer, CF, Sun, P, Lubinski, J & Narod, SA 2016, 'Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case–control study', Breast Cancer Research and Treatment, vol. 155, no. 2, pp. 365-373. https://doi.org/10.1007/s10549-016-3685-3
Kotsopoulos, Joanne ; Huzarski, Tomasz ; Gronwald, Jacek ; Moller, Pal ; Lynch, Henry T. ; Neuhausen, Susan L. ; Senter, Leigha ; Demsky, Rochelle ; Foulkes, William D. ; Eng, Charis ; Karlan, Beth ; Tung, Nadine ; Singer, Christian F. ; Sun, Ping ; Lubinski, Jan ; Narod, Steven A. / Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers : a case–control study. In: Breast Cancer Research and Treatment. 2016 ; Vol. 155, No. 2. pp. 365-373.
@article{eb456a76a09d457c917a84ce53e889ee,
title = "Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case–control study",
abstract = "Many BRCA1 mutation carriers undergo elective surgical oophorectomy (often before menopause) to manage their elevated risk of developing ovarian cancer. It is important to clarify whether or not the use of hormone replacement therapy (HRT) to mitigate the symptoms associated with surgical or natural menopause is safe in women with an inherited BRCA1 mutation and no personal history of breast or ovarian cancer. We conducted a case–control analysis of 432 matched pairs of women with a BRCA1 mutation. Detailed information on HRT use after menopause (duration, type, age at first/last use, formulation) was obtained from a research questionnaire administered at the time of study enrollment. Conditional logistic regression was used to estimate the odds ratio (OR) and 95 {\%} confidence intervals (CI) associated with HRT use. The mean duration of HRT use after menopause was 4.3 years among the cases and 4.4 years among the controls (P = 0.83). The adjusted OR for breast cancer comparing all women who ever used HRT to those who never used HRT was 0.80 (95 {\%} CI 0.55–1.16; P = 0.24). Findings did not differ by type of menopause (natural vs. surgical), by recency of use, by duration of use, and by formulation type. These findings suggest that a short course of HRT should not be contra-indicated for BRCA1 mutation carriers who have undergone menopause and who have no personal history of cancer.",
author = "Joanne Kotsopoulos and Tomasz Huzarski and Jacek Gronwald and Pal Moller and Lynch, {Henry T.} and Neuhausen, {Susan L.} and Leigha Senter and Rochelle Demsky and Foulkes, {William D.} and Charis Eng and Beth Karlan and Nadine Tung and Singer, {Christian F.} and Ping Sun and Jan Lubinski and Narod, {Steven A.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/s10549-016-3685-3",
language = "English",
volume = "155",
pages = "365--373",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers

T2 - a case–control study

AU - Kotsopoulos, Joanne

AU - Huzarski, Tomasz

AU - Gronwald, Jacek

AU - Moller, Pal

AU - Lynch, Henry T.

AU - Neuhausen, Susan L.

AU - Senter, Leigha

AU - Demsky, Rochelle

AU - Foulkes, William D.

AU - Eng, Charis

AU - Karlan, Beth

AU - Tung, Nadine

AU - Singer, Christian F.

AU - Sun, Ping

AU - Lubinski, Jan

AU - Narod, Steven A.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Many BRCA1 mutation carriers undergo elective surgical oophorectomy (often before menopause) to manage their elevated risk of developing ovarian cancer. It is important to clarify whether or not the use of hormone replacement therapy (HRT) to mitigate the symptoms associated with surgical or natural menopause is safe in women with an inherited BRCA1 mutation and no personal history of breast or ovarian cancer. We conducted a case–control analysis of 432 matched pairs of women with a BRCA1 mutation. Detailed information on HRT use after menopause (duration, type, age at first/last use, formulation) was obtained from a research questionnaire administered at the time of study enrollment. Conditional logistic regression was used to estimate the odds ratio (OR) and 95 % confidence intervals (CI) associated with HRT use. The mean duration of HRT use after menopause was 4.3 years among the cases and 4.4 years among the controls (P = 0.83). The adjusted OR for breast cancer comparing all women who ever used HRT to those who never used HRT was 0.80 (95 % CI 0.55–1.16; P = 0.24). Findings did not differ by type of menopause (natural vs. surgical), by recency of use, by duration of use, and by formulation type. These findings suggest that a short course of HRT should not be contra-indicated for BRCA1 mutation carriers who have undergone menopause and who have no personal history of cancer.

AB - Many BRCA1 mutation carriers undergo elective surgical oophorectomy (often before menopause) to manage their elevated risk of developing ovarian cancer. It is important to clarify whether or not the use of hormone replacement therapy (HRT) to mitigate the symptoms associated with surgical or natural menopause is safe in women with an inherited BRCA1 mutation and no personal history of breast or ovarian cancer. We conducted a case–control analysis of 432 matched pairs of women with a BRCA1 mutation. Detailed information on HRT use after menopause (duration, type, age at first/last use, formulation) was obtained from a research questionnaire administered at the time of study enrollment. Conditional logistic regression was used to estimate the odds ratio (OR) and 95 % confidence intervals (CI) associated with HRT use. The mean duration of HRT use after menopause was 4.3 years among the cases and 4.4 years among the controls (P = 0.83). The adjusted OR for breast cancer comparing all women who ever used HRT to those who never used HRT was 0.80 (95 % CI 0.55–1.16; P = 0.24). Findings did not differ by type of menopause (natural vs. surgical), by recency of use, by duration of use, and by formulation type. These findings suggest that a short course of HRT should not be contra-indicated for BRCA1 mutation carriers who have undergone menopause and who have no personal history of cancer.

UR - http://www.scopus.com/inward/record.url?scp=84955757551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955757551&partnerID=8YFLogxK

U2 - 10.1007/s10549-016-3685-3

DO - 10.1007/s10549-016-3685-3

M3 - Article

C2 - 26780555

AN - SCOPUS:84955757551

VL - 155

SP - 365

EP - 373

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -